ATHA

Athira Pharma, Inc. (ATHA) Economic Moat Analysis (2026)

Invetso Score: 2/10 — Weak · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Intangible Assets

Score: 2.0 (Weak)

ATHA’s available metrics show negative ROIC and ROCE, which indicates the business is not converting any presumed brand or IP advantage into durable economic returns versus peers.

No filing-based evidence provided here shows proprietary technology, regulated exclusivity, or protected intellectual property that would create pricing power or retention advantages over comparable peers.

With no demonstrated margin resilience or positive capital returns, any intangible asset base appears insufficient to support a durable moat relative to peers.

Switching Costs

Score:

The negative ROIC and ROCE suggest customers are not locked in by high switching friction, because a strong switching-cost moat typically supports sustained excess returns.

No evidence provided indicates contractual lock-in, workflow embedding, data migration burden, or compliance dependency that would make ATHA materially harder to replace than peers.

Compared with stronger software or platform peers, ATHA appears to have limited retention leverage, so switching costs do not currently support durable pricing power.

Network Effects

Score:

The provided data do not show user, transaction, or data-network flywheels that would make the business more valuable as adoption rises.

Negative returns on capital are inconsistent with a peer-leading network effect that would normally translate into scale-driven margin expansion and retention.

Relative to peers with clear ecosystem or marketplace dynamics, ATHA shows no evidence of self-reinforcing demand that would strengthen moat durability.

Cost Advantage

Score:

A negative ROIC and ROCE profile argues against a structural cost advantage, because a lower-cost operator should usually sustain better capital efficiency than peers.

The available efficiency data do not indicate superior asset productivity, and asset turnover is reported at zero, which does not support a cost-led moat.

Against peers, ATHA does not appear to have a durable procurement, manufacturing, or operating-cost edge that would protect margins over 5–10 years.

Efficient Scale

Score:

The current metrics do not evidence efficient-scale economics, because a business with natural scale advantages should typically show stronger capital returns as fixed costs are spread.

No filing or third-party evidence provided here suggests ATHA operates in a market where one or a few incumbents can serve demand at materially lower cost than peers.

Relative to peers, ATHA does not appear to benefit from a protected niche or capacity-constrained market structure that would limit new entry and preserve returns.

Overall Score

Score:

ATHA currently shows no visible durable moat in the provided evidence, as negative capital returns and weak efficiency metrics do not support pricing power, retention, or structural advantage versus peers.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Athira Pharma, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →